Mutations in KRAS are seen in ~ 27% of lung adenocarcinomas, and in total, ~ 76% of tumors harbor mutations in RTK-Ras-Raf pathway genes including the tyrosine kinases EGFR and MET [2, 11, 22]. Here, KRAS is linked to lung adenocarcinoma.